• Home
  • Portfolio
  • Insights
  • About
  • Contact
Understanding pseudoxanthoma elasticum: Insights from Orfenix

Understanding pseudoxanthoma elasticum: Insights from Orfenix

by Hellen Houlleberghs | Apr 14, 2025 | Blog

At Orfenix, our mission is to develop therapies for unmet medical needs. One such need is a treatment for pseudoxanthoma elasticum (PXE), a rare genetic disorder that significantly impacts patients’ lives. Heleen van Loenen, head of the Dutch PXE patient organisation,...
Mastering EMA Briefing Documents: Essential Tips and Tricks

Mastering EMA Briefing Documents: Essential Tips and Tricks

by Hellen Houlleberghs | Nov 21, 2024 | Blog

Understanding EMA scientific advice The European Medicines Agency (EMA) scientific advice procedure was introduced with the aim to improve communication between companies developing medicinal products (sponsors) and regulators to enable streamlining of the development...

Recent Posts

  • Understanding pseudoxanthoma elasticum: Insights from Orfenix
  • Exclusive to be inclusive, the ethics of exclusivity
  • Should I use an existing (generic) medicinal product or develop a new one for a repurposed indication? 
  • Challenges in Clinical Trials for Orphan Drugs
  • Mastering EMA Briefing Documents: Essential Tips and Tricks

Recent Comments

No comments to show.

Contact us

Langegracht 70
2312NV Leiden
The Netherlands

+31(0)71 523 45 67
info@orfenix.com

 

Orfenix repurposes existing compounds to create sustainable and affordable therapies, focusing on accessible healthcare through innovative and collaborative efforts.

Do you want to collaborate? Let us know on investors@orfenix.com

 

  • Follow